ERα and ERRα contribute prostate cancer (PC) progression via phosphatidylinositol-3 kinase (Pl3K), mitogen-activated protein kinase (MAPK) and Vascular Endothelial Growth Factor A (VEGF-A), Wnt Family Member 5A (WNT5A), and Transforming Growth Factor Beta 1 (TGFβ1) VEGF/WNT5A/TGF pathways, respectively. This evidence concerns the gene ESR1 and prostate carcinoma.